Objective: The aim of this study was to explore the treatment effect of olanzapine on the polymorphisms of monoamine oxidase A (MAOA) in schizophrenia. Method: During a 3-month period, 60 patients with schizophrenia were administered olanzapine. Treatment response was assessed by checking for improvement in symptoms as measured on the Positive and Negative Syndrome Scale (PANSS). Results: The short form of MAOA demonstrated a better drug response in the dimension of aggression. Female patients had a better response to olanzapine. Patients who did not smoke had a better response to olanzapine in the dimension of aggression. Conclusion: The results of this study suggest that polymorphisms of MAOA, gender, and cigarette smoking may be three useful response predictors in schizophrenic patients who were treated with olanzapine.